PE20040042A1 - Composicion farmaceutica que comprende esteres de etonogestrel - Google Patents
Composicion farmaceutica que comprende esteres de etonogestrelInfo
- Publication number
- PE20040042A1 PE20040042A1 PE2003000508A PE2003000508A PE20040042A1 PE 20040042 A1 PE20040042 A1 PE 20040042A1 PE 2003000508 A PE2003000508 A PE 2003000508A PE 2003000508 A PE2003000508 A PE 2003000508A PE 20040042 A1 PE20040042 A1 PE 20040042A1
- Authority
- PE
- Peru
- Prior art keywords
- ester
- etonogestrel
- contraceptive
- pharmaceutical composition
- composition including
- Prior art date
Links
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical class O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000002148 esters Chemical class 0.000 abstract 3
- 229960002941 etonogestrel Drugs 0.000 abstract 3
- 239000003433 contraceptive agent Substances 0.000 abstract 2
- 230000002254 contraceptive effect Effects 0.000 abstract 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 abstract 2
- YSGQGNQWBLYHPE-CFUSNLFHSA-N (7r,8r,9s,10r,13s,14s,17s)-17-hydroxy-7,13-dimethyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 YSGQGNQWBLYHPE-CFUSNLFHSA-N 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 206010036618 Premenstrual syndrome Diseases 0.000 abstract 1
- 239000003098 androgen Substances 0.000 abstract 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 abstract 1
- 239000002583 male contraceptive agent Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02077118 | 2002-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040042A1 true PE20040042A1 (es) | 2004-01-31 |
Family
ID=29595013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000508A PE20040042A1 (es) | 2002-05-30 | 2003-05-26 | Composicion farmaceutica que comprende esteres de etonogestrel |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20050222114A1 (https=) |
| EP (1) | EP1513588B1 (https=) |
| JP (1) | JP2005532336A (https=) |
| KR (1) | KR20050005507A (https=) |
| CN (1) | CN1655848A (https=) |
| AR (1) | AR040129A1 (https=) |
| AT (1) | ATE394140T1 (https=) |
| AU (1) | AU2003246740B2 (https=) |
| BR (1) | BR0311248A (https=) |
| CA (1) | CA2487293A1 (https=) |
| DE (1) | DE60320786D1 (https=) |
| ES (1) | ES2305498T3 (https=) |
| HR (1) | HRP20041127A2 (https=) |
| IL (1) | IL165125A0 (https=) |
| IS (1) | IS7537A (https=) |
| MX (1) | MXPA04011798A (https=) |
| NO (1) | NO20044903L (https=) |
| NZ (1) | NZ536618A (https=) |
| PE (1) | PE20040042A1 (https=) |
| PL (1) | PL373295A1 (https=) |
| RS (1) | RS101004A (https=) |
| RU (1) | RU2322986C2 (https=) |
| TW (1) | TW200400041A (https=) |
| UA (1) | UA80703C2 (https=) |
| WO (1) | WO2003101374A2 (https=) |
| ZA (1) | ZA200409498B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200403065A (en) * | 2002-05-30 | 2004-03-01 | Akzo Nobel Nv | New etonogestrel esters |
| US20130123523A1 (en) * | 2011-11-10 | 2013-05-16 | Klaus Nickisch | Methods for the preparation of etonogestrel and desogestrel |
| DE102012211511A1 (de) * | 2012-07-03 | 2014-01-09 | Siemens Aktiengesellschaft | Bestimmung der Eignung einer Ressource |
| US10624903B2 (en) * | 2017-10-19 | 2020-04-21 | Evestra, Inc. | Longer-acting progestin prodrug contraceptives |
| CN111057120B (zh) * | 2019-12-27 | 2021-04-27 | 苏州翔实医药发展有限公司 | 一种依托孕烯衍生物a及其制备方法和用途 |
| US20230227492A1 (en) * | 2020-06-11 | 2023-07-20 | The Usa As Represented By The Secretary, Department Of Health And Human Services | Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4227989A1 (de) * | 1992-08-21 | 1994-06-09 | Schering Ag | Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel |
| DE4240806A1 (de) * | 1992-12-01 | 1994-06-09 | Schering Ag | Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol |
| JPH07101884A (ja) * | 1993-10-01 | 1995-04-18 | Sanei Gen F F I Inc | 水溶性ヘミセルロースを含有する製剤 |
| HUT75159A (en) * | 1993-12-27 | 1997-04-28 | Akzo Nobel Nv | Percutaneously absorbable preparation, containing 3-ketodesogestrel and 17 beta-estradiol |
| EP0848620A1 (de) * | 1995-07-17 | 1998-06-24 | Schering Aktiengesellschaft | Mittel zur transdermalen applikation enthaltend ester des 3-ketodegestrel |
| WO1999067270A1 (en) * | 1998-06-19 | 1999-12-29 | Akzo Nobel N.V. | Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone) |
| NZ508299A (en) * | 1998-06-19 | 2003-04-29 | Akzo Nobel Nv | Testosterone derivative |
| US6180682B1 (en) * | 1999-01-26 | 2001-01-30 | Virgil A. Place | Buccal drug delivery system for use in male contraception |
| TW200403065A (en) * | 2002-05-30 | 2004-03-01 | Akzo Nobel Nv | New etonogestrel esters |
-
2003
- 2003-05-19 TW TW092113492A patent/TW200400041A/zh unknown
- 2003-05-22 BR BR0311248-9A patent/BR0311248A/pt not_active IP Right Cessation
- 2003-05-22 RU RU2004138809/15A patent/RU2322986C2/ru active
- 2003-05-22 NZ NZ536618A patent/NZ536618A/en unknown
- 2003-05-22 EP EP03755980A patent/EP1513588B1/en not_active Expired - Lifetime
- 2003-05-22 AU AU2003246740A patent/AU2003246740B2/en not_active Ceased
- 2003-05-22 US US10/517,362 patent/US20050222114A1/en not_active Abandoned
- 2003-05-22 PL PL03373295A patent/PL373295A1/xx not_active Application Discontinuation
- 2003-05-22 CN CNA038123657A patent/CN1655848A/zh active Pending
- 2003-05-22 CA CA002487293A patent/CA2487293A1/en not_active Abandoned
- 2003-05-22 MX MXPA04011798A patent/MXPA04011798A/es unknown
- 2003-05-22 DE DE60320786T patent/DE60320786D1/de not_active Expired - Fee Related
- 2003-05-22 AT AT03755980T patent/ATE394140T1/de not_active IP Right Cessation
- 2003-05-22 UA UA20041109285A patent/UA80703C2/uk unknown
- 2003-05-22 KR KR10-2004-7019327A patent/KR20050005507A/ko not_active Withdrawn
- 2003-05-22 JP JP2004508732A patent/JP2005532336A/ja not_active Withdrawn
- 2003-05-22 ES ES03755980T patent/ES2305498T3/es not_active Expired - Lifetime
- 2003-05-22 RS YU101004A patent/RS101004A/sr unknown
- 2003-05-22 WO PCT/EP2003/050188 patent/WO2003101374A2/en not_active Ceased
- 2003-05-22 HR HR20041127A patent/HRP20041127A2/hr not_active Application Discontinuation
- 2003-05-26 PE PE2003000508A patent/PE20040042A1/es not_active Application Discontinuation
- 2003-05-28 AR ARP030101858A patent/AR040129A1/es unknown
-
2004
- 2004-11-09 IL IL16512504A patent/IL165125A0/xx unknown
- 2004-11-10 NO NO20044903A patent/NO20044903L/no not_active Application Discontinuation
- 2004-11-18 IS IS7537A patent/IS7537A/is unknown
- 2004-11-24 ZA ZA200409498A patent/ZA200409498B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2305498T3 (es) | 2008-11-01 |
| WO2003101374A3 (en) | 2004-02-26 |
| RU2322986C2 (ru) | 2008-04-27 |
| IL165125A0 (en) | 2005-12-18 |
| AU2003246740B2 (en) | 2009-01-08 |
| EP1513588B1 (en) | 2008-05-07 |
| RU2004138809A (ru) | 2005-06-10 |
| AU2003246740A1 (en) | 2003-12-19 |
| DE60320786D1 (de) | 2008-06-19 |
| HK1072568A1 (en) | 2005-09-02 |
| CN1655848A (zh) | 2005-08-17 |
| PL373295A1 (en) | 2005-08-22 |
| US20050222114A1 (en) | 2005-10-06 |
| IS7537A (is) | 2004-11-18 |
| BR0311248A (pt) | 2005-03-15 |
| EP1513588A2 (en) | 2005-03-16 |
| NO20044903L (no) | 2005-02-25 |
| NZ536618A (en) | 2007-06-29 |
| RS101004A (sr) | 2006-10-27 |
| CA2487293A1 (en) | 2003-12-11 |
| UA80703C2 (en) | 2007-10-25 |
| JP2005532336A (ja) | 2005-10-27 |
| ZA200409498B (en) | 2006-05-31 |
| TW200400041A (en) | 2004-01-01 |
| MXPA04011798A (es) | 2005-03-31 |
| KR20050005507A (ko) | 2005-01-13 |
| HRP20041127A2 (en) | 2005-02-28 |
| ATE394140T1 (de) | 2008-05-15 |
| WO2003101374A2 (en) | 2003-12-11 |
| AR040129A1 (es) | 2005-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2011001712A1 (es) | Combinacion de 0,1 a 1 mg de al menos un estimulador de sgc seleccionado de un grupo definido con 2,5 a 20 mg de un inhibidor de pde5 seleccionado de otro grupo; formulacion farmaceutica que la comprende y uso en el tratamiento de la disfuncion sexual masculina. | |
| MX352328B (es) | Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos. | |
| ATE478129T1 (de) | Kerzenwachs auf triacylglycerin-basis | |
| CY1106064T1 (el) | Τυποποιηση ενος εστερα τεστοστepονης για ανθρωπινη χρηση | |
| ECSP066670A (es) | Prodroga florfenicol con mejor solubilidad en agua | |
| DE602004026303D1 (de) | Behandlung von entzündlichen erkrankungen | |
| UA102478C2 (en) | Capsule composition | |
| RU2012125827A (ru) | Применение аналога тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции | |
| AR117404A2 (es) | Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación | |
| AP2003002742A0 (en) | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | |
| EA200801602A1 (ru) | Эмульсия | |
| TW200631597A (en) | External use preparation and adhesive preparation thereof | |
| BRPI0512991A (pt) | uso de uma progestina, kit farmaceuticamente útil adaptado para a administração oral diária, e, método de contracepção em uma fêmea em idade de parto | |
| ECSP088571A (es) | Control de la estabilidad de la forma de dosificacion de cci-779 a traves del control de impurezas de sustancias de farmaco | |
| MX2016014411A (es) | Formulacion liquida que comprende un compuesto neutralizante de gm-csf. | |
| CL2012002705A1 (es) | Composicion farmaceutica que comprende: a) 0,1-20% de ropivacaina,bupivacaina o levobupivacaina, b) 15 a 70% en peso de un monoglicerido de acido graso de cadena larga o sus mezclas, c) 5 a 60% de un acido graso libre saturado o instaurado de cadena larga y d)menos de 30% de agua; uso para reducir el dolor. | |
| AR048833A1 (es) | Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos | |
| PE20040992A1 (es) | Combinaciones sinergicas entre un ligando alfa-2-delta y un inhibidor de pdev | |
| PE20040042A1 (es) | Composicion farmaceutica que comprende esteres de etonogestrel | |
| CO2023013397A2 (es) | Compuestos de tienopirrol | |
| CO5631449A2 (es) | Nuevos esteres de etonogestrel | |
| AR054123A1 (es) | Composicion farmaceutica que contienen gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato | |
| CO5160323A1 (es) | Formulaciones farmaceuticas mejoradas vir en combinacion con otros inhibidores de proteasa vih | |
| MX2019012681A (es) | Composiciones nutricionales y farmaceuticas encapsuladas. | |
| AR106835A1 (es) | Mezcla con bajo contenido de grasa saturada para usarse para revestimiento de barrera contra la humedad en confituras congeladas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal | ||
| AE | Restoration of lapsed or forfeited application | ||
| FC | Refusal |